/PRNewswire/ Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced that positive data from a Phase 2 study of AMG 451/KHK4083 were.
The study met its primary objective of demonstrating statistically greater improvement from baseline in Eczema Area and Severity Index score at 16 weeks versus placeboPatients receiving KHK4083/AMG 451 showed statistically greater improvements in additional secondary efficacy endpoints versus placeboKHK4083/AMG 451.
American Skin Association Announces 2021 Research Grants for Skin Cancer and Diseases
News provided by
Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ American Skin Association has announced the awarding of two coveted research grants under the
ASA Milstein Research Scholar Awards program
.
ASA Milstein Research Scholar Award for Melanoma/Non-Melanoma Skin Cancer and
Ester Del Duca, MD of the Icahn School of Medicine at Mount Sinai received the
ASA Milstein Research Scholar Award in Atopic Dermatitis.
This year of grants includes the
ASA Daneen & Charles Stiefel Investigative Scientist Award in Melanoma Research awarded to
Elena Piskonouva, PhD of Weill Cornell Medicine. The Stiefel Family, longtime supporters of ASA, generously contributed $300,000 to support grants for melanoma research. The purpose of this funding is to identify and support emerging leaders in dermatology focused on melanoma research. Specifically catering to mid-ca
Pelle psoriasi-free, su Nejm 2 studi promuovono monoclonale Ucb yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis
February 18, 2021 GMT
TOKYO (BUSINESS WIRE) Feb 18, 2021
For Medical Media only. Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announces today that the Phase 2 study of investigational agent KHK4083 in patients with atopic dermatitis has met the primary endpoint.
KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company’s patented POTELLIGENT ® defucosylation technology to enhance its antibody dependent cellular cytotox